Replies to post #100778 on Amarantus Bioscience Holdings Inc (AMBS)

[SouthBreeze]

I thought it was very interesting that Gerald didn't mention MANF's orphan indication in the field of diabetes.

...at that point in time when MANF was discussed, which incidentally was at the end of the presentation, GC made a point of mentioning the time factor in his presentation. Although he did make a point to mention Retinitus Pigmentosa primarily as a MANF driven degenerative disease to look at...

[Riskreturn168]

I'd love it if there were an NDA in place on Diabetes, but I don't think we do .Dr. Lowe's said in the CC that we didn't want to move Diabetes forward until we consulted more with Diabetes experts. Dr. Urano said something similar about us in his blog a month ago. According to both Lowe and Urano, our expertise is in Parkinsons, not Diabetes. Dr. Urano told his blog audience that he was glad we were interested in Diabetes, though. We've got some catching up to do before we corner the diabetes market!!

Retinitis is our lead program for MANF, and it is enough for now.
One new thing that was a positive from Gerald today was that he said we'd gotten a "functionality test" completed for Retinitis and the results were positive. That signals that we'll be moving Retinitis forward as fast as possible!!